Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of angiotensin II injection for distributive shock
CTR20251955Phase 3Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of Angiotensin II in Vasoplegia, septic shock, sponsored by Yichang Humanwell Pharmaceutical Co., Ltd.. Started Jul 2025; status: completed.
02
Drugs
Angiotensin II
03
Conditions
Vasoplegiaseptic shock
Beyond the preview
Go deeper on CTR20251955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251955.